US2005089522A1PendingUtilityA1

Methods of inhibiting osteoclastogenesis

54
Assignee: IMMUNEX CORPPriority: May 14, 1998Filed: Nov 30, 2004Published: Apr 28, 2005
Est. expiryMay 14, 2018(expired)· nominal 20-yr term from priority
Inventors:Dirk M. AndersonLaurent Galibert
A61P 43/00A61P 35/04A61P 19/08C07K 2319/00C07K 2319/73C07K 2319/30C07K 14/70578A61P 19/10C07K 14/70575Y10S530/866A61K 2039/505A61K 38/00
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided here are methods of inhibiting RANKL-induced osteoclastogenesis in patients suffering from specific types of cancer.

Claims

exact text as granted — not AI-modified
1 . A method of inhibiting RANK-induced osteoclastogenesis in a cancer patient in need thereof, said method comprising administering to said patient a monoclonal antibody that specifically binds a RANKL polypeptide comprising amino acids 70-317 of SEQ ID NO:8, wherein said patient suffers from bone cancer.  
     
     
         2 . A method of inhibiting RANK-induced osteoclastogenesis in a cancer patient in need thereof, said method comprising administering to said patient a monoclonal antibody that specifically binds a RANKL polypeptide comprising amino acids 70-317 of SEQ ID NO:8, wherein said patient suffers from multiple myeloma.  
     
     
         3 . A method of inhibiting RANK-induced osteoclastogenesis in a cancer patient in need thereof, said method comprising administering to said patient a monoclonal antibody that specifically binds a RANKL polypeptide comprising amino acids 70-317 of SEQ ID NO:8, wherein said patient suffers from melanoma.  
     
     
         4 . A method of inhibiting RANK-induced osteoclastogenesis in a cancer patient in need thereof, said method comprising administering to said patient a monoclonal antibody that specifically binds a RANKL polypeptide comprising amino acids 70-317 of SEQ ID NO:8, wherein said patient suffers from breast cancer.  
     
     
         5 . A method of inhibiting RANK-induced osteoclastogenesis in a cancer patient in need thereof, said method comprising administering to said patient an antibody that specifically binds a RANKL polypeptide comprising amino acids 70-317 of SEQ ID NO:8, wherein said patient suffers from squamous cell carcinoma.  
     
     
         6 . A method of inhibiting RANK-induced osteoclastogenesis in a cancer patient in need thereof, said method comprising administering to said patient an antibody that specifically binds a RANKL polypeptide comprising amino acids 70-317 of SEQ ID NO:8, wherein said patient suffers from lung cancer.  
     
     
         7 . A method of inhibiting RANK-induced osteoclastogenesis in a cancer patient in need thereof, said method comprising administering to said patient an antibody that specifically binds a RANKL polypeptide comprising amino acids 70-317 of SEQ ID NO:8, wherein said patient suffers from prostate cancer.   that specifically binds a RANKL polypeptide comprising amino acids 70-317 of SEQ ID NO:8, wherein said patient suffers from hematologic cancer.  
     
     
         9 . A method of inhibiting RANK-induced osteoclastogenesis in a cancer patient in need thereof, said method comprising administering to said patient an antibody that specifically binds a RANKL polypeptide comprising amino acids 70-317 of SEQ ID NO:8, wherein said patient suffers from head and neck cancer.  
     
     
         10 . A method of inhibiting RANK-induced osteoclastogenesis in a cancer patient in need thereof, said method comprising administering to said patient an antibody that specifically binds a RANKL polypeptide comprising amino acids 70-317 of SEQ ID NO:8, wherein said patient suffers from renal cancer.

Join the waitlist — get patent alerts

Track US2005089522A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.